AAPL   366.27 (+0.59%)
MSFT   207.10 (+1.17%)
FB   233.87 (-1.55%)
AMZN   2,897.95 (+0.67%)
NVDA   385.90 (+1.23%)
CGC   16.56 (+0.55%)
GE   6.84 (+1.48%)
TSLA   1,210.92 (+8.15%)
AMD   52.43 (-0.30%)
T   30.16 (+0.84%)
GILD   76.52 (+0.60%)
DIS   112.54 (-0.42%)
NFLX   479.73 (-1.22%)
BA   181.14 (+0.45%)
AAPL   366.27 (+0.59%)
MSFT   207.10 (+1.17%)
FB   233.87 (-1.55%)
AMZN   2,897.95 (+0.67%)
NVDA   385.90 (+1.23%)
CGC   16.56 (+0.55%)
GE   6.84 (+1.48%)
TSLA   1,210.92 (+8.15%)
AMD   52.43 (-0.30%)
T   30.16 (+0.84%)
GILD   76.52 (+0.60%)
DIS   112.54 (-0.42%)
NFLX   479.73 (-1.22%)
BA   181.14 (+0.45%)
AAPL   366.27 (+0.59%)
MSFT   207.10 (+1.17%)
FB   233.87 (-1.55%)
AMZN   2,897.95 (+0.67%)
NVDA   385.90 (+1.23%)
CGC   16.56 (+0.55%)
GE   6.84 (+1.48%)
TSLA   1,210.92 (+8.15%)
AMD   52.43 (-0.30%)
T   30.16 (+0.84%)
GILD   76.52 (+0.60%)
DIS   112.54 (-0.42%)
NFLX   479.73 (-1.22%)
BA   181.14 (+0.45%)
AAPL   366.27 (+0.59%)
MSFT   207.10 (+1.17%)
FB   233.87 (-1.55%)
AMZN   2,897.95 (+0.67%)
NVDA   385.90 (+1.23%)
CGC   16.56 (+0.55%)
GE   6.84 (+1.48%)
TSLA   1,210.92 (+8.15%)
AMD   52.43 (-0.30%)
T   30.16 (+0.84%)
GILD   76.52 (+0.60%)
DIS   112.54 (-0.42%)
NFLX   479.73 (-1.22%)
BA   181.14 (+0.45%)
Log in

NASDAQ:HJLIHancock Jaffe Laboratories Stock Price, Forecast & News

$0.41
+0.02 (+5.06 %)
(As of 07/2/2020 03:44 PM ET)
Add
Compare
Today's Range
$0.38
Now: $0.41
$0.43
50-Day Range
$0.32
MA: $0.38
$0.47
52-Week Range
$0.21
Now: $0.41
$1.20
Volume563,290 shs
Average Volume2.02 million shs
Market Capitalization$9.94 million
P/E RatioN/A
Dividend YieldN/A
Beta1.79
Hancock Jaffe Laboratories, Inc., a development stage medical device company, develops and sells biological tissue solutions to treat patients with coronary, vascular, end stage renal, and peripheral arterial diseases in the United States and Europe. The company develops and manufactures implantable cardiovascular bioprosthetic devices for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease. Its products include the Bioprosthetic Heart Valve, a bio-prosthetic heart valve designed to mimic and function like a native heart valve; the CoreoGraft, a device for use as an alternate or supplemental coronary vascular conduit in coronary bypass surgery; and the Venous Valve, a bioprosthetic, pig venous valve for patients with lower limb chronic venous insufficiency. The company was founded in 1987 and is headquartered in Irvine, California. As of July 18, 2006, Hancock Jaffe Laboratories, Inc. is a subsidiary of Leman Cardiovascular SA.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.16 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HJLI
CUSIPN/A
Phone949-261-2900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$30,000.00
Book Value$0.06 per share

Profitability

Net Income$-7,630,000.00

Miscellaneous

EmployeesN/A
Market Cap$9.94 million
Next Earnings Date8/3/2020 (Estimated)
OptionableNot Optionable

Receive HJLI News and Ratings via Email

Sign-up to receive the latest news and ratings for HJLI and its competitors with MarketBeat's FREE daily newsletter.

Hancock Jaffe Laboratories (NASDAQ:HJLI) Frequently Asked Questions

How has Hancock Jaffe Laboratories' stock been impacted by COVID-19 (Coronavirus)?

Hancock Jaffe Laboratories' stock was trading at $0.50 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, HJLI stock has decreased by 17.0% and is now trading at $0.4149. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Hancock Jaffe Laboratories?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hancock Jaffe Laboratories in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Hancock Jaffe Laboratories.

When is Hancock Jaffe Laboratories' next earnings date?

Hancock Jaffe Laboratories is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Hancock Jaffe Laboratories.

How were Hancock Jaffe Laboratories' earnings last quarter?

Hancock Jaffe Laboratories Inc (NASDAQ:HJLI) issued its quarterly earnings results on Monday, June, 8th. The company reported ($0.06) earnings per share for the quarter. View Hancock Jaffe Laboratories' earnings history.

What price target have analysts set for HJLI?

1 Wall Street analysts have issued 12-month target prices for Hancock Jaffe Laboratories' stock. Their forecasts range from $3.00 to $3.00. On average, they expect Hancock Jaffe Laboratories' stock price to reach $3.00 in the next year. This suggests a possible upside of 623.1% from the stock's current price. View analysts' price targets for Hancock Jaffe Laboratories.

Has Hancock Jaffe Laboratories been receiving favorable news coverage?

News stories about HJLI stock have trended very negative this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Hancock Jaffe Laboratories earned a coverage optimism score of -3.3 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about Hancock Jaffe Laboratories.

Who are some of Hancock Jaffe Laboratories' key competitors?

What other stocks do shareholders of Hancock Jaffe Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hancock Jaffe Laboratories investors own include Amarin (AMRN), VBI Vaccines (VBIV), Vaxart (VXRT), Agile Therapeutics (AGRX), Advanced Micro Devices (AMD), Crispr Therapeutics (CRSP), Fortress Biotech (FBIO), Protalix Biotherapeutics (PLX), vTv Therapeutics (VTVT) and Acasti Pharma (ACST).

Who are Hancock Jaffe Laboratories' key executives?

Hancock Jaffe Laboratories' management team includes the following people:
  • Mr. Robert A. Berman, CEO & Director (Age 56)
  • Mr. Robert Rankin, CFO, Sec. & Treasurer (Age 66)
  • Dr. Benedict Broennimann M.D., Chief Medical Officer of Outside of United States (Age 62)
  • Dr. Marc H. Glickman, Sr. VP & Chief Medical Officer (Age 70)
  • Mr. Warren Hancock, Co-founder

When did Hancock Jaffe Laboratories IPO?

(HJLI) raised $8 million in an IPO on Thursday, May 31st 2018. The company issued 1,500,000 shares at $5.00 per share. Network 1 Financial Securities acted as the underwriter for the IPO and ViewTrade Securities was co-manager.

What is Hancock Jaffe Laboratories' stock symbol?

Hancock Jaffe Laboratories trades on the NASDAQ under the ticker symbol "HJLI."

How do I buy shares of Hancock Jaffe Laboratories?

Shares of HJLI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Hancock Jaffe Laboratories' stock price today?

One share of HJLI stock can currently be purchased for approximately $0.41.

How big of a company is Hancock Jaffe Laboratories?

Hancock Jaffe Laboratories has a market capitalization of $9.94 million and generates $30,000.00 in revenue each year.

What is Hancock Jaffe Laboratories' official website?

The official website for Hancock Jaffe Laboratories is www.hancockjaffe.com.

How can I contact Hancock Jaffe Laboratories?

Hancock Jaffe Laboratories' mailing address is 70 DOPPLER, IRVINE CA, 92618. The company can be reached via phone at 949-261-2900.

This page was last updated on 7/2/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.